Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 11:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 819 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Autonomic Nervous System Diseases Clear all

Conditions: Postural Orthostatic Tachycardia Syndrome, Syncope, Vasovagal, Neurocardiogenic Syncope
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 10 Years to 21 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Diabetes
Interventions: Aliskiren, Placebo; Drug · Other
Lead sponsor: Christiana Care Health Services; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Parkinson Disease, Autonomic Dysfunction, Depression
Interventions: transcranial magnetic stimulation; Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 50 Years to 90 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Cornelia de Lange Syndrome
Interventions: Autonomic Dysfunction Testing; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 8 Years to 18 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Syncope, Vasovagal
Interventions: Buzzy®, Music; Device · Behavioral
Lead sponsor: Duke University; Other
Eligibility: 10 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 2
States / cities: Atlanta, Georgia • Durham, North Carolina

Conditions: Shy-Drager Syndrome, Multiple System Atrophy
Interventions: Pseudoephedrine + 480 ml water, Pseudoephedrine + 50 ml water, Placebo + 480 ml water (optional), Placebo + 50 ml water (optional); Drug · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Autonomic Failure, Orthostatic Hypotension
Interventions: Abdominal binder, No abdominal binder; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Orthostatic Hypotension, Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy
Interventions: automated abdominal binder, Sham binder, Placebo, Midodrine; Device · Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 40 Years to 80 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: OBESITY, HYPERTENSION, PURE AUTONOMIC FAILURE, SHY-DRAGER SYNDROME
Interventions: Trimethaphan, Pseudoephedrine; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Type 2 Diabetes Mellitus
Interventions: Glucagon-Like Peptide- 1 (GLP-1) infusion, Placebo Comparator: Saline Infusion; Drug · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 45 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Osteoarthritis, Arthritis
Interventions: NSAID, tanezumab; Drug · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 2,720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 250
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 161 more

Conditions: Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
Interventions: Not listed
Lead sponsor: The Parkinson Study Group; Network
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2007
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Type 1 Diabetes
Interventions: Dehydroepiandrosterone, Placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Spinal Cord Injury
Interventions: InTENsity MicroCombo; Device
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
Interventions: Ampreloxetine, Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 30 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 26
States / cities: Scottsdale, Arizona • Fountain Valley, California • La Jolla, California + 21 more

Conditions: Postural Orthostatic Tachycardia Syndrome
Interventions: Blood Volume, Total Blood Volume, Exercise Capacity Test - Bicycle, Posture Study; Radiation · Procedure
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Psychological Stress
Interventions: Essential Oil Inhalation, Placebo Aroma Stick; Other
Lead sponsor: dōTERRA International; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Pleasant Grove, Utah

Conditions: Pain
Interventions: clonidine, adenosine, placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Not listed
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 2
States / cities: Winston-Salem, North Carolina

Conditions: Pain
Interventions: OraVescent Fentanyl; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 21
States / cities: Hot Springs, Arkansas • Los Gatos, California • Oxnard, California + 16 more

Conditions: Amyotrophic Lateral Sclerosis, Neurodegenerative Disease, Motor Neuron Disease
Interventions: Not listed
Lead sponsor: Drexel University College of Medicine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Osteoarthritis, Rheumatoid Arthritis, Chronic Low Back Pain, Chronic Regional Pain Syndrome, Chronic Soft Tissue Pain
Interventions: HZT-501, Ibuprofen; Drug
Lead sponsor: Amgen; Industry
Eligibility: 40 Years to 81 Years
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: San Diego, California

Conditions: Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease
Interventions: ROC-101; Drug
Lead sponsor: AllRock Bio, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 11
States / cities: Phoenix, Arizona • Rancho Cordova, California • Aurora, Colorado + 8 more

Conditions: HR+ HER2- Breast Cancer
Interventions: Serabelisib, Sapanisertib, Fulvestrant; Drug
Lead sponsor: Faeth Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 7
States / cities: Los Angeles, California • Lone Tree, Colorado • Springfield, Oregon + 3 more

Conditions: Hypotension, Orthostatic
Interventions: Treatment Phase 1, Treatment Phase 2, Treatment Phase 3; Other · Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

Tilt Table With Suspected Postural Orthostatic Tachycardia Syndrome (POTS) Subjects

The Effect of Renin Inhibition on Nerve Function in Diabetes

Investigating Central Neurophysiologic Correlates of Non-Motor Symptoms of Parkinson's Disease

Evaluation of Autonomic Function in Individuals With Cornelia de Lange Syndrome (CdLS)

Preventing Post-Vaccination Presyncope and Syncope in Adolescents Using Simple, Clinic-based Interventions: A Pilot Study

Water and Sudafed in Autonomic Failure

Abdominal Compression in Orthostatic Hypotension

Automated Abdominal Binder for Orthostatic Hypotension

The Autonomic Nervous System and Obesity

GLP-1 and Hypoglycemia

Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip

Diagnostic and Prognostic Biomarkers in Parkinson Disease

Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus

Vagal Nerve Stimulation to Reduce Inflammation and Hyperadrenergia

Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy

Dietary Salt in Postural Tachycardia Syndrome

Essential Oil Inhalation and Acute Stress Response in Healthy Adults

Clonidine Versus Adenosine to Treat Neuropathic Pain

Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain

Assessment of the Cyberlink Control System for Use by the Amyotrophic Lateral Sclerosis (ALS) Patient

Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216)

A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

Orthostatic Hypotension in Rehabilitation Patients